Secure payment on i-micronews Contact Yole Développement for I Micronews reports

RSS I-micronewsYole Dévelopement on TwitterYole Développement on Google +LinkedIn Yole pageSlideshare Yole Développement I-Micronews

Non-Invasive Glucose Monitoring Patent Landscape

3 990 €

Choose a minimum of three reports from Yole Group and receive a discount of at least 36% on your package – Contact us!


Icone Non Invasive Glucose Patent Landscape ReportWith the entry of new companies, such as Google, the field of non-invasive glucose monitoring is expected to grow rapidly, with new innovative and accurate devices

The patent landscape for non-invasive glucose monitoring is really rich, involving many players exploring various technical approaches, such as IR spectroscopy, photoacoustic or impedance. It includes more than 1,600 patent families filed and involves over 500 applicants.

With 387 million people concerned worldwide by diabetes in 2014 (International Diabetes Federation) and an ever growing number of diabetics, the market related to diabetes management is considerable and very attractive. The global glucose monitoring device market is estimated to reach $14,2 billion by 2019 by Mordor Intelligence.
To this date, the conventional technique to measure glucose still involves drawing blood (finger pricking), which can cause pain and discomfort for the patient. Hence, the need to find a non-invasive technique to monitor glucose.

Many companies have tried to develop non-invasive technology and device for glucose monitoring, but so far with no success. A few devices had obtained approval from the authorities in the USA or Europe before being abandoned : GlucoWatch (Cygnus), Pendra (Pendragon Medical), NBM-200G (OrSense) or HG1-c (C8 MediSensors). Recently, Integrity Applications received the European CE Mark and launched its GlucoTrack DF-F device late 2014 in Europe. While several minimally-invasive devices are now commercially available, bringing to the market a totally non-invasive device would represent a great change for the market and the diabetics. The renewed IP interest for this topic observed recently shows the desire of players to overcome the same cause of failure faced in the last 3 decades, reliability and accuracy of the technology. The IP and the market for non-invasive monitoring of glucose are driven by the ever increasing diabetic population around the world as well as the recent sizeable democratization of wearable sensors for health monitoring.

Patents related to Non Invasive Devices

The spectrum of technologies investigated to monitor glucose non-invasively is very broad. Spectrometry is the most trendy technology. Spectrometry regroups various techniques, but they don’t all receive the same focus. The spectrum of sample targets studied to perform a non-invasive measurement is also really broad. The detection of glucose level at the skin level or in the blood vessels are the most investigated. But techniques allowing a detection at the level of the eye are also considered and a new comer in the non-invasive glucose monitoring domain is investing mostly in this approach.

Most main players are industrial companies, involved in the diabetes business or in the monitoring of various blood parameters.
With many players and many technical approaches studied and no great success on the market yet, the non-invasive glucose monitoring IP domain is evolving regularly.
The report provides a ranking and analysis of the relative strength of the top patent holders derived from their portfolio size, patent citations networks, countries of patents filings, current legal status of patents. Through this thorough analysis, we have identified 15 major players, each of which is profiled in this report. Each profile includes a detailed portfolio analysis with patent activities, key patents, impact of portfolio, granted patents near expiration and IP strategies.

Leadership of Patent Applicants

Many American and Japanese companies feature in the top-20 of the main assignee ranking for the non-invasive glucose monitoring technology. However, the analysis of the main current IP applicants shows that the IP landscape is changing, with companies changing their technology focus and others entering the domain. Moreover, academic applicants are filling more applications than in the past. The same way, several Chinese companies are also showing interest in the domain lately.

Mapping of Main Current IP Applicants

Key patents have been identified based on several indicators, including family size, legal status, citations analysis and impact on non-invasive glucose monitoring technology.
This patent landscape shows that the major IP holders are not necessarily the most influent players in the domain. Several key patents filed by companies who have ceased their activity are still granted and have been acquired by others.

Our report also includes an Excel database containing all of the analyzed patents. This database allows for multi-criteria searches and includes patent publication number, hyperlinks to the original documents, priority date, title, abstract, patent assignees and legal status for each member of the patent family.

Key Patent Families
The report provides essential patent data for non-invasive glucose monitoring including:

  • Time evolution of patent publications and countries of patent filings
  • Current legal status of patents
  • Ranking of main patent applicants
  • Joint developments and IP collaboration network of main patent applicants
  • Key patents
  • Granted patents near expiration
  • Relative strength of main companies IP portfolio
  • Non-invasive glucose monitoring IP profiles of 15 major companies with key patents, partnerships, and IP strength and strategy

The report also provides an extensive Excel database with all patents analyzed in the study


  • Understand the IP landscape for non-invasive glucose monitoring
  • Identify key patents
  • Understand trends in non-invasive glucose monitoring IP
  • Classify the major players in non-invasive glucose monitoring IP and the relative strength of their patent portfolio
  • Identify new players in non-invasive glucose monitoring IP
  • Identify IP collaboration networks between key players


Table of contents

Introduction 3

Authors  4
Key Features of the Report  5
Objectives of the Report  7
Scope of the Report  8
Terminology for Patent Analysis  9
Methodology  11
Search Strategy  13
Main Industrial Assignees Mentioned 14
Main Academic Assignees Mentioned  18
Technology Overview  20

Executive Summary  22

IP Overview  26

Time Evolution of Patent Publications 27
Countries of Patent Filings  28
Time Evolution by Country of Filing 29
Current Legal Status of Patents in the Portfolio  30
Ranking of Main Industrial Patent Applicants  31
Ranking of Main Academic Patent Applicants  32
Time Evolution for Main Patent Applicants  33
Countries of Filings for Main Patent Applicants  34
Mapping of Main Current IP Holders 35
Mapping of Main Current IP Applicants  36
Main IPC Classes  37
Time Evolution by IPC  38
Matrix Main Applicants / Main IPC 39
Technical Issues  40
Summary of Applicant’s Patent Portfolio  43
Leadership of Patent Applicants  45
Degree of Specialization in Non-Invasive Glucose  46
Citations analysis  47
Strength of Patent Portfolios  48
IP Blocking Potential of Patent Applicants  49
Patent Applicants IP Network  50
Key Patent Families  51
Granted Patents Near Expiration  52

Main Patent Litigations  54
Dominion Assets vs Masimo & Cercacor  55
Echo Therapeutics vs David J. Kappos  56
CME Telemetrix vs Sensys Medical 57
Potential Future Plaintiffs  58

Non-Invasive Devices for Glucose Monitoring  59

GlucoWatch – Cygnus (Animas Technologies)  61
Pendra – Pendragon Medical  65
NMB-200G – OrSense  66
HG1-c – C8 Medisensors  69
GlucoTrack DF-F – Integrity Applications  70

Key Players  72

Key Player Selection  73
Panasonic  74
Sensys Medical  76
Abbott  78
Cercacor  80
Masimo  82
Animas Technologies  84
Futrex  87
Samsung Electronics  89
Bayer Healthcare  91
Toshiba  93
InLight Solutions  95
Roche Diagnostics  97
OrSense  99
Google  101
Integrity Applications  103

Conclusions  105

Annex  109 

Companies cited

Animas Technologies
Bayer Healthcare
InLight Solutions
Integrity Applications
Masimo Laboratories
Roche Diagnostic
Samsung Electronic
Sensys Medical


The report provides:

  • Time evolution of patent publications and countries of patent filings.
  • Current legal status of patents.
  • Ranking of main patent applicants.
  • Joint developments and IP collaboration network of main patent applicants.
  • Key patents.
  • Granted patents near expiration.
  • Relative strength of main companies IP portfolio.
  • Photoacoustic imaging IP profiles of 15 major companies with key patents, partnerships, and IP strength and strategy.
  • Extensive Excel database with all patents analyzed in the study.